# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹328 Cr** (+9% YoY) * **Gross Margin:** **76%** (+700 bps YoY, +700 bps QoQ) * **EBITDA:** **₹98 Cr** (+18% YoY) · **EBITDA Margin:** **30%** * **Finance Costs:** **₹19 Cr** (vs. ₹24 Cr YoY) · **Net Debt:** **₹550 Cr** (as of Jun 30) * Capex: ₹70 Cr (Q1 FY'26) · Tax Rate (Q1): 5.5% ## B. Revenue Growth * **Strong Segment Momentum:** Revenue growth driven by robust performance in **API and Biologic verticals**, with full transparency on captive sales to improve comparability. * **Captive Utilization:** Approximately **₹40 Cr** of API revenue attributed to captive consumption, highlighting vertical integration benefits. ## C. Gross Margins * **Margin Expansion:** Gross margin surged to 76%, reflecting favorable product mix and inclusion of high-margin items such as licensing fees and profit-sharing. * **Sustainability Note:** Management cautions that elevated margins in the quarter include non-recurring high-margin contributions and should not be extrapolated as a sustained trend. ## D. EBITDA & Profitability * **Record Profitability:** Highest-ever quarterly EBITDA achieved, supported by strong operating performance and strategic asset monetization initiatives. * **Finance Cost Dynamics:** Mark-to-market loss of **₹5 Cr** from euro-denominated debt impacted finance costs; underlying costs declined, with normalized run rate expected near **₹14 Cr**. * **Tax Outlook:** Despite a low effective tax rate of 5% this quarter, full-year rate is expected to normalize to **35–36%**, factoring out one-time benefits from INM Technologies’ unabsorbed losses. ## E. Balance Sheet & Debt * **Debt Refinancing Clarity:** High-cost NCDs worth **₹75 Cr** replaced with lower-cost debt, reducing interest burden—clarified as refinancing, not repayment, to correct prior disclosure misinterpretation. * **Strategic Amalgamation:** NCLT approval for merger of INM Technologies enables tax loss set-off, reducing prior-year tax outflow and improving cash flow efficiency. * **Liquidity Initiative:** Bonus issue announced to enhance stock liquidity and reward long-term shareholders, addressing constraints from sub-10 crore share base. --- # 2. Product & Therapy Performance ## A. Key Figures * **API Revenue:** **₹187 Cr** (+8% YoY) * **Biosimilars Revenue:** **₹73 Cr** * **Biologics Revenue:** **₹37 Cr** (+270% QoQ from ₹10 Cr) * **Formulation Revenue:** **₹98 Cr** ## B. API Segment Growth * **Record Segment Performance:** API division achieved highest-ever Q1 results, driven by portfolio rationalization and ramp-up of expanded capacities. * **Strong Forward Momentum:** Robust order book for generics and rising captive consumption—led by Nilotinib, Axitinib, and Nor-Ursodeoxycholic acid—support sustained oncology-focused growth. * **Pipeline Progress:** Palbociclib DMF filing imminent; Olaparib validation underway with filing expected after stability data; Teriflunomide API commercialized. ## C. Biologics & Biosimilars * **High-Growth CDMO Engine:** Biologics revenue surged on new CDMO deals, with five active preclinical/Phase I programs laying foundation for future scale. * **Global Biosimilar Ambition:** Nivolumab to be first biosimilar advanced into human studies (Q4 FY26), targeting U.S. and Europe; Albumin remains on global development path. * **Revenue Composition:** Current biologics income largely from CDMO and licensing, with material biosimilar sales expected post-launch in regulated markets. ## D. NCE & CDMO Projects * **Breakthrough NCE Milestone:** Nor-Ursodeoxycholic acid (NorUDCA) approved and launched as Shilpa’s first in-house developed NCE, targeting NAFLD—a condition affecting **over 40%** of Indian patients. * **Differentiated Launch Trajectory:** Bortezomib expected to outpace Pemetrexed’s ramp-up by ~1 quarter, validating repeatable commercial execution. * **Pipeline Depth:** Four additional differentiated NCEs in formulation pipeline; CDMO revenue reporting to be segmented by API, FDF, and Biologics in coming quarters. ## E. Formulation Launches * **Export Market Strength:** Nilotinib maintains strong European demand; Axitinib launched in April with solid order book; multiple new launches expected in Europe within 6–8 months. * **Peptide Commercialization Underway:** Desmopressin and Octreotide Acetate in active commercial supply across Europe, U.S., and ROW, with **two-quarter order book visibility** for Desmopressin. * **Advanced Development:** Registration batches completed for **SMLOSD014**, a differentiated anticoagulant, signaling near-term regulatory submission. --- # 3. R&D & Clinical Progress ## A. Key Figures * **Nivolumab:** Application submitted for **Phase I/III human trials**, aiming for study initiation by end of year * **Albumin Phase III:** Study start expected in **Q4FY26**, with **12–15 months trial duration** and **~1 year approval process**, targeting **commercial launch by end of FY'28 or early FY'29** * **Aflibercept Phase III:** Study ongoing for India and ROW, expected completion within current financial year, enabling **commercialization next year** ## B. Phase III Trials * **Oncology Pipeline Momentum:** Two NCE programs advancing, with one nearing commercialization next year and the other in active Phase III trials set to conclude by next year. * **Global Patch Rollout:** Rotigotine transdermal patch under EU review with approval expected in 2HFY'26; U.S. filing planned for Q3FY'26 following near-complete clinical studies. * **Biosimilar Progress:** Nivolumab moves toward human trials, while Alveolus Bio and mAbTree (NBEs) and first ADC program are on track to enter human studies next year. * **Completed Trials:** Phase III for SMLINJ011 completed in India, with approval filing preparation underway. ## C. Regulatory Filings * **Non-Oncology Expansion:** Mycophenolate Mofetil (non-oncology) completed process validation; DMF and CEP filings expected with 6-month stability data. * **Liraglutide Filing Path:** API and formulation registration batches on track for combined global filing after completion by end-September. * **D. S. Albumin Strategy:** Clinical study plan submission scheduled for Q3, with FDA feedback expected in Q4 to clarify U.S. development timeline. ## D. Product Development * **NCE Commercialization Path:** Nor-UDCA API supply expected from 2QFY26; two CDMO NCEs—one for gallbladder (with **FDA Breakthrough Therapy designation**) and OLC—set for launch next year and FY'27 respectively. * **Semaglutide Timeline:** API development complete; registration batches to begin in Q3FY26, targeting completion by end-Q4FY26. * **Strategic Complex Portfolios:** Four biosimilars in development with cell lines ready; recombinant human albumin scale-up initiated with Orion partnership; long-term focus remains on NCEs, NBEs, and ADCs. ## E. Global Study Alignment * **Regulatory Convergence:** Evolving biosimilar strategy leverages potential acceptance of India-conducted studies by European regulators, enabling globally aligned trials; similar pathway targeted for U.S. --- # 4. Manufacturing & Capacity ## A. Key Figures * **Ursodeoxycholic Acid Production:** **>10 MT/month** run rate achieved * **Stability Data Submitted:** **1-year** stability data submitted for Unicycive CMO transfer * **Stability Data Generated:** **6-month** stability data supporting upcoming DMF/CEP filings for two oncology products ## B. Plant Expansions * **Commercial Ramp-Up Underway:** Tranexamic acid capacity expansion complete, with commercial supplies initiated in 1QFY26, boosting sales turnover. ## C. CMO Transfers * **Critical Transfer Resolved:** Technology transfer for Unicycive contract successfully completed to a new U.S. FDA and EU-approved CMO, mitigating prior delays. ## D. Scale-Up Progress * **Oncology Pipeline Advancing:** Two new oncology products cleared process validation, with regulatory filings (DMF/CEP) expected within 6 months. * **GLP-1 Exposure Building:** Tirzepatide lab development finalized, with scale-up set to begin in Q3FY26, establishing early-mover positioning in high-growth GLP-1 market. --- # 5. Partnerships & Commercialization ## A. Key Figures * **Licensing Income:** **₹57 Cr** (Q1, includes Orion deal proceeds) * **CDMO Projects:** **25+ active projects** (preclinical to Phase III) · **2 expected to commercialize next year** * **NDA-Approved Products:** **3 products** commercialized in U.S. via partners (revenue upcoming post reconciliation) ## B. Licensing Deals * **Strategic Verticals:** Business organized into **API, Formulations, and Biologics**, with targeted growth initiatives across each segment. * **High-Potential Polymer Supply:** Second specialty polymer delivered to major pharma for use in an **NCE application**, signaling strong CDMO traction and future revenue potential. * **NorUDCA Launch Imminent:** Product approved at central level, state licenses expected within **15–20 days**, with **tentative October launch**; all launch orders secured. * **Multi-Partner Commercialization:** NorUDCA to be launched by **four entities total**, including **three Indian partners** (one top-tier), generating dual revenue streams from **licensing and supply sales**; partner disclosure expected after one quarter. ## C. Launch Partners * **Top-Tier Channel Access:** NorUDCA partnered with **three companies among the top 10 IPM firms**, ensuring broad market reach and commercial credibility. ## D. Supply Agreements * **Steady CDMO Revenue Pipeline:** Commercial supply underway for MNC polymer project (Q1 start, expected through 2HFY26), with **replenishment order anticipated**, supporting revenue visibility. * **E. S. Market Contribution Ahead:** Revenue from **three NDA-approved products** in U.S. expected in upcoming quarters following profit share reconciliation. ## E. Milestone Payments * **Orion Deal Recognized:** Full **₹57 Cr licensing income** recognized in quarter; no further financial details disclosed due to confidentiality. * **Unicycive Progress Ongoing:** Tablet supply agreement in place for June 2025 delivery; commercialization remains on track for next financial year pending final CMO data. * **Biologics R&D Efficiency:** Investments in **Alveolus and mAbTree** will not drive incremental R&D spend in FY '27 due to existing infrastructure; Shilpa to supply **clinical trial materials exclusively** for Phase I. --- # 6. Pricing & Market Dynamics ## A. Market Size Revisions * **Revised Market Definition:** The reported reduction in SMLINJ011 market size reflects a **narrower segmentation** focused on highly emetic patients, repositioning the product as a specialty treatment rather than a broad-market offering. ## B. Competitive Landscape * **ROW Growth Drivers:** Recent international sales increase driven by **multi-product contribution** and commercial momentum from **registrations secured over the past three years**. --- # 7. Regulatory & Clinical Risks ## A. Regulatory Milestones & Inspections * **FDA Approval Unlocked:** Shilpa received an EIR from the U.S. FDA for its transdermal patch facility, enabling commercial entry into the U.S. market. * **Pending Surprise Inspection:** FDA audit of the formulation plant expected imminently as a no-notice inspection, representing a key near-term regulatory risk. ## B. Clinical & Filing Strategy * **Unicycive Filing Timing:** Decision pending on whether to file with 1-year or 6-month stability data; submission expected next financial year if based on 1-year data. * **Lenvatinib Status Withheld:** Management declined to disclose updates on Lenvatinib following prior adverse outcome, citing market sensitivity and strategic considerations. * **Selective Disclosure Policy:** No information will be shared until a reasonable outcome is achieved, indicating cautious approach to at-risk launch speculation. --- # 8. Guidance & Outlook ## A. Capex Plans * **Capex Mitigation Strategy:** Global trial funding for key assets (albumin, NorUDCA, SMLINJ011, biosimilars) will be de-risked through **partnering at strategic stages**, generating licensing fees to offset costs. * **API Investment in Pipeline:** Additional investments in the API business are planned for FY '26–'27, with full capex details to be disclosed in the next quarterly update. ## B. Launch Timelines